Global Information
회사소개 | 문의 | 위시리스트

세계의 바이오시뮬레이션 시장 분석

Global Bio-simulation Market Research And Forecast 2018-2023

리서치사 Orion Market Research Pvt Ltd
발행일 2018년 07월 상품 코드 425937
페이지 정보 영문
가격
US $ 3,600 ₩ 4,383,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,844,000 Printable PDF (Enterprise License)


세계의 바이오시뮬레이션 시장 분석 Global Bio-simulation Market Research And Forecast 2018-2023
발행일 : 2018년 07월 페이지 정보 : 영문

세계의 바이오시뮬레이션(Biosimulation) 시장에 대해 조사 분석했으며, 시장 영향요인, 지역별 규제와 정책, 시장 결정요인, 매출 예측, 주요 기업 프로파일과 최근 동향 등의 정보를 전해드립니다.

제1장 보고서 요약

제2장 시장 개요와 고찰

  • 정의
  • 갭 분석
  • 역사적 분석
  • 현재 시장 동향
  • 애널리스트 고찰
  • 규제

제3장 시장 결정요인

  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제4장 시장 세분화

  • 용도별
  • 제품별
  • 최종사용자별 등

제5장 경쟁 구도

  • 주요 전략 분석
  • 주요 기업 분석

제6장 지역별 분석

  • 북미
  • 유럽
  • 아시아태평양 지역
  • 기타

제7장 기업 개요

  • CERTARA US, INC.
  • SIMULATION PLUS INC
  • DASSAULT SYSTEMES SA
  • SCHRODINGER INC.
  • ADVANCED CHEMISTRY DEVELOPMENT, INC.
  • CHEMICAL COMPUTING GROUP, INC.
  • ENTELOS HOLDING CORPORATION
  • GENEDATA AG
  • PHYSIOMICS PLC
  • RHENOVIA PHARMA LTD
  • ACCELRYS INC.
  • LEADSCOPE
  • INSILICO BIOSCIENCES
  • COMPUGEN
  • NIMBUS HEALTHCARE
  • INSILICO BIOSCIENCES INC
  • INHIBOX
  • JOHNSON & JOHNSON
  • BIOVIA
  • LEADINVENT TECHNOLOGIES
LSH 17.02.06

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • TABLE # 1 GLOBAL BIO-SIMULATION MARKET RESEARCH AND FORECAST BY GEOGRAPHY 2017-2023, ($ MILLION)
  • TABLE # 2 GLOBAL BIO-SIMULATION MARKET RESEARCH AND FORECAST BY APPLICATIONS 2017-2023, ($ MILLION)
  • TABLE # 3 GLOBAL BIO-SIMULATION APPLICATION MARKET RESEARCH AND FORECAST BY DRUG DEVELOPMENT 2017-2023, ($ MILLION)
  • TABLE # 4 GLOBAL PRECLINICAL TESTING MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 5 GLOBAL PK/PD MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 6 GLOBAL GLOBALISM/TOX MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 7 GLOBAL CLINICAL TRIALS MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 8 GLOBAL BIO-SIMULATION APPLICATION MARKET RESEARCH AND FORECAST BY DRUG DISCOVERY 2017-2023, ($MILLION)
  • TABLE # 9 GLOBAL TARGET IDENTIFICATION AND VALIDATION MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 10 GLOBAL LEAD IDENTIFICATION AND OPTIMIZATION MARKET RESEARCH AND FORECAST 2017-2023, ($ MILLION)
  • TABLE # 11 GLOBAL BIO-SIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 12 GLOBAL BIO-SIMULATION PRODUCT MARKET RESEARCH AND FORECAST BY SOFTWARE 2017-2023, ($MILLION)
  • TABLE # 13 GLOBAL PK/PD MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 14 GLOBAL MOLECULAR MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 15 GLOBAL PBPK MODELLING AND SIMULATION SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 16 GLOBAL TOXICITY PREDICTION SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($ MILLION)
  • TABLE # 17 GLOBAL TRIAL DESIGN SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 18 GLOBAL OTHER SOFTWARE MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 19 GLOBAL SERVICES MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 20 GLOBAL EXTERNAL/CONTRACT SERVICES MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 21 GLOBAL BIO-SIMULATION MARKET RESEARCH AND FORECAST BY END USERS, 2017-2023, ($ MILLION)
  • TABLE # 22 GLOBAL BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES MARKET RESEARCH AND FORECAST, 2017-2023, ($MILLION)
  • TABLE # 23 GLOBAL DRUG DISCOVERY AND DRUG DEVELOPMENT COMPANY MARKET RESEARCH AND FORECAST, 2017-2023 ($MILLION)
  • TABLE # 24 GLOBAL EDUCATION CENTERS AND RESEARCH INSTITUTES MARKET RESEARCH AND FORECAST, 2017-2023 ($MILLION)
  • TABLE # 25 GLOBAL REGULATORY AUTHORITIES MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 26 GLOBAL OTHER END USERS MARKET RESEARCH AND FORECAST 2017-2023, ($MILLION)
  • TABLE # 27 NORTH AMERICA BIO-SIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 28 NORTH AMERICA BIO-SIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT, 2017-2023 ($ MILLION)
  • TABLE # 29 NORTH AMERICA BIO-SIMULATION MARKET RESEARCH AND FORECAST BY END USERS, 2017-2023 ($ MILLION)
  • TABLE # 30 EUROPE BIO-SIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2017-2023 ($ MILLION)
  • TABLE # 31 EUROPE BIO-SIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 32 EUROPE BIO-SIMULATION MARKET RESEARCH AND FORECAST BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 33 APAC BIO-SIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION 2017-2023, ($ MILLION)
  • TABLE # 34 APAC BIO-SIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT 2017-2023, ($ MILLION)
  • TABLE # 35 APAC BIO-SIMULATION MARKET RESEARCH AND FORECAST BY END USERS 2017-2023, ($ MILLION)
  • TABLE # 36 REST OF THE WORLD BIO-SIMULATION MARKET RESEARCH AND FORECAST BY APPLICATION, 2017-2023, ($ MILLION)
  • TABLE # 37 REST OF THE WORLD BIO-SIMULATION MARKET RESEARCH AND FORECAST BY PRODUCT, 2017-2023 ($ MILLION)
  • TABLE # 38 REST OF THE WORLD BIO-SIMULATION MARKET RESEARCH AND FORECAST BY END USERS, 2017-2023 ($ MILLION)

List of Figures

  • FIGURE # 1 GLOBAL BIO-SIMULATION MARKET SHARE BY APPLICATION 2017 VS 2023 (IN %)
  • FIGURE # 2 GLOBAL BIO-SIMULATION MARKET SHARE BY PRODUCT 2017 VS 2023 (IN %)
  • FIGURE # 3 GLOBAL BIO-SIMULATION MARKET SHARE BY END USERS 2017 VS 2023 (IN %)
  • FIGURE # 4 GLOBAL BIO-SIMULATION MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
  • FIGURE # 5 NORTH AMERICA BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 6 US BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 7 CANADA BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 8 EUROPEAN BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 9 UK BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 10 FRANCE BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 11 GERMANY BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 12 ITALY BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 13 SPAIN BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 14 ROE BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 15 ASIA PACIFIC BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 16 INDIA BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 17 CHINA BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 18 JAPAN BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 19 ROAPAC BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)
  • FIGURE # 20 REST OF THE WORLD BIO-SIMULATION MARKET SIZE 2017-2023 ($MILLION)

Global Bio-simulation Market is predicted to grow significantly with a CAGR 15.5% during 2018-2023 due to rise in adoption of drug discovery and development and success in precision dosing. There are other pivotal factors that are driving the market which includes rising inclination towards personalized medicine, biomedicine and other research projects. Bio-simulation applications such as preclinical testing, clinical trials, target identification and validation, lead identification and optimization are widely adopted. These applications enable to provide faster and more certain results compared to conventional techniques as a result it is widely adopted across the globe. The technological advancement and innovation in Bio-simulation products and applications enable to reduce the number of clinical studies for drug development.

Model-based drug development reduces the clinical studies and offer better results. Bio-simulation have huge contribution in personalized medicines which are adopted widely for better patient care. Due to the advancement in bio-simulation the traditional one size fits all concept is replaced by personalized medicines. Bio-simulation models enable to find better protection against various diseases such as tumour and other cancer cases through precise dozing. As a result, it saves time, effort and money for drug development for many diseases. Bio-simulation technology offers virtual clinical trial population for paediatric, elderly and other group of patients. It enables to perform better clinical trials and reduce the time and effort for drug discovery and development.

Global Bio-simulation Market is expected to grow significantly due to rise in adoption of drug discovery and development, personalized medicine and success of precision dozing. The successful outcome of research & development and critical FDA approvals enable the Bio-simulation Market to grow fast. Funding from government and private players are also key factors to drive the Global Bio-simulation Market. However, high cost of global Bio-simulation products and application are concern for the growth of the market.

North America generates highest revenues across the globe due to huge adoption of Bio-simulation technology and highest rate of healthcare spending followed by Europe. Untapped APAC region such as China, India, Japan and Korea are the most emerging economies and expected to create huge opportunity for Bio-simulation Market. Improved healthcare spending, infrastructure development and favourable government policies are the key factors which are expected to drive the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Market Segmentation, Geographical Analysis, Pipeline Analysis, Strategic Recommendations, Key Company Analysis, Key Findings, Market Insights, Analyst Insights and predictive analysis of the market.

The key players of Global Biosimulation Market includes Certara Us, Inc., Simulation Plus Inc.,Dassault Systemes SA, Schrodinger Inc.,Advanced Chemistry Development, Inc., Chemical Computing Group, Inc., Entelos Holding Corporation, Genedata AG, Physiomics PLC, Rhenovia Pharma Ltd, Accelrys Inc., Leadscope, Insilico Biosciences, Compugen, Nimbus Healthcare, Insilico Biosciences Inc., Inhibox, Johnson & Johnson, Biovia, Leadinvent Technologies and so on. The key strategies adopted by the market players include R&D, partnership, FDA approval, product development, innovation and so on.

The Report covers:

  • Comprehensive research methodology of Global bio-simulation Market.
  • This report also includes detailed and extensive market overview with Analyst insights & key market trends.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Global bio-simulation Market.
  • Insights about market determinants which are stimulating the Global bio-simulation Market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. REPORT SUMMARY

  • 1.1. RESEARCH METHODS AND TOOLS
  • 1.2. MARKET BREAKDOWN
    • 1.2.1. BY SEGMENTS
    • 1.2.2. BY GEOGRAPHY
    • 1.2.3. BY STAKEHOLDERS

2. MARKET OVERVIEW AND INSIGHTS

  • 2.1. DEFINITION
  • 2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
    • 2.2.1. KEY FINDINGS
    • 2.2.2. RECOMMENDATION
    • 2.2.3. CONCLUSION
  • 2.3. REGULATIONS
    • 2.3.1. UNITED STATES
    • 2.3.2. EUROPEAN UNION
    • 2.3.3. CHINA
    • 2.3.4. INDIA
    • 2.3.5. REST OF THE WORLD

3. MARKET DETERMINANT

  • 3.1. MOTIVATORS
    • 3.1.1. GLOBAL RISE IN ADOPTION OF DRUG DISCOVERY AND DEVELOPMENT
    • 3.1.2. GROWING ADOPTION OF PERSONALIZED MEDICINES
    • 3.1.3. TECHNOLOGICAL ADVANCEMENT AND INNOVATION IN GLOBAL BIO-SIMULATION MARKET
    • 3.1.4. COHESIVE GOVERNMENT POLICIES AND REGULATIONS
    • 3.1.5. GLOBAL RISE IN HEALTHCARE EXPENDITURE
    • 3.1.6. R&D TO DRIVE THE BIO-SIMULATION MARKET
  • 3.2. RESTRAINTS
    • 3.2.1. HIGH COST OF BIO-SIMULATION IS A CONCERN FOR THE MARKET
    • 3.2.2. CHANCES OF ERROR IN BIO-SIMULATION MODEL DEVELOPMENT APPROACHES
    • 3.2.3. SOFTWARE FOR LARGE SCALE BIO-SIMULATIONS MAY CREATE PROBLEM AND COMPLEXITY
  • 3.3. OPPORTUNITIES
    • 3.3.1. GLOBAL RISE IN PHARMACEUTICAL MARKET IS EXPECTED TO BOOST THE GLOBAL BIO-SIMULATION MARKET
    • 3.3.2. R&D OUTCOMES OF DRUG DEVELOPMENT IN NEXT FEW YEARS ARE EXPECTED TO DRIVE THE GLOBAL BIO-SIMULATION MARKET
    • 3.3.3. CLINICAL TRIALS ARE PREDICTED TO INCREASE IN NEXT FEW YEARS
    • 3.3.4. REDUCTION IN LATE STAGE ATTRITION

4. MARKET SEGMENTATION

  • 4.1. BIO-SIMULATION MARKET BY APPLICATION
    • 4.1.1. DRUG DEVELOPMENT
      • 4.1.1.1. GLOBAL PRECLINICAL TESTING
      • 4.1.1.2. GLOBAL PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD)
      • 4.1.1.3. GLOBALISM/TOX
      • 4.1.1.4. GLOBAL CLINICAL TRIALS
    • 4.1.2. DRUG DISCOVERY
      • 4.1.2.1. TARGET IDENTIFICATION AND VALIDATION
      • 4.1.2.2. LEAD IDENTIFICATION AND OPTIMIZATION
    • 4.1.3. OTHER APPLICATIONS
  • 4.2. BIO-SIMULATION MARKET BY PRODUCT
    • 4.2.1. SOFTWARE
      • 4.2.1.1. PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELLING AND SIMULATION SOFTWARE
      • 4.2.1.2. MOLECULAR MODELLING AND SIMULATION SOFTWARE
      • 4.2.1.3. PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING (PBPK) MODELLING AND SIMULATION SOFTWARE
      • 4.2.1.4. TOXICITY PREDICTION SOFTWARE
      • 4.2.1.5. TRIAL DESIGN SOFTWARE
      • 4.2.1.6. OTHER SOFTWARE
    • 4.2.2. SERVICES
    • 4.2.3. EXTERNAL/CONTRACT SERVICES
  • 4.3. BIO-SIMULATION MARKET BY END USERS
    • 4.3.1. BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES
    • 4.3.2. DRUG DISCOVERY AND DRUG DEVELOPMENT COMPANIES
    • 4.3.3. EDUCATION CENTRES AND RESEARCH INSTITUTES
    • 4.3.4. REGULATORY AUTHORITIES
    • 4.3.5. OTHER

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
  • 5.2. KEY COMPANY ANALYSIS

6. REGIONAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. UNITED STATES
    • 6.1.2. CANADA
    • 6.1.3. REST OF NORTH AMERICA
  • 6.2. EUROPE
    • 6.2.1. UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. SPAIN
    • 6.2.6. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. INDIA
    • 6.3.2. CHINA
    • 6.3.3. JAPAN
  • 6.4. REST OF THE WORLD

7. COMPANY PROFILES

  • 7.1. ACCELRYS
  • 7.2. ACD/LABS
  • 7.3. BIOVIA
  • 7.4. CERTARA
  • 7.5. CHEMICAL COMPUTING GROUP
  • 7.6. COMPUGEN
  • 7.7. DASSAULT SYSTEMES
  • 7.8. ENTELOS HOLDING CORPORATION
  • 7.9. GENEDATA
  • 7.10. IN SILICO BIOSCIENCES INC.
  • 7.11. INHIBOX
  • 7.12. JOHNSON & JOHNSON
  • 7.13. LEADINVENT
  • 7.14. LEADSCOPE
  • 7.15. NIMBUS HEALTHCARE
  • 7.16. PHYSIOMICS RATIONAL THERAPEUTICS
  • 7.17. RHENOVIA PHARMA
  • 7.18. SCHRODINGER
  • 7.19. SIMULATION PLUS
Back to Top
전화 문의
F A Q